one team

Arndt, a clinical professor of neurology and psychiatry, is a multi-entrepreneur in biotechnology, founder and CEO of Agyany Pharmaceuticals. He has founded international biotechnology and healthcare companies over the past 20 years, including an IPO on Nasdaq in 2019 with Centogene AG (Nasdaq: CTNG), a company he founded. Arndt is also a leader in the field of complex genetic disease research and novel biomarkers to predict disease and prevent health problems. He has led several international multicentre studies in rare diseases and is actively involved in biomarker research for many genetic diseases. With an extensive track record of over 400 peer-reviewed clinical, medical and scientific publications, "a lifelong commitment to our patients" is what drives Arndt every day. In addition, Arndt holds several honorary professorships and doctorates, as well as international patents.

Professor Ari Zimran was the founder and director of the Gaucher Unit at Shaare Zedek Medical Center in Jerusalem from 1990 to 2018, and is currently a senior physician in the Unit. This is the world’s largest referral center for Gaucher Disease (GD), having monitored more than 900 patients to date, and currently treating about 400 patients with enzyme replacement and substrate reduction therapies. Professor Zimran developed his interest in GD during his fellowship at the Scripps Research Institute, Department of Molecular and Experimental Medicine in La Jolla, California under the mentorship of Professor Ernest Beutler. Professor Zimran has published more than 320 professional papers and reviews and has edited three books, and has been a leader in clinical trials for new treatments for GD, including Cerezyme™, Zavesca™, VPRIV™, Elelyso™, Cerdelga™ and Ambroxol. His most recent research focuses include the relationship between GD and Parkinson, the development of oral enzyme replacement therapy, and gene therapy.

Noel Müller is a seasoned finance and investment professional and began his career at Credit Suisse Investment Bank, where he rose from an Analyst to Vice President in M&A, working in Zurich and New York. In this role, Noel worked on numerous transactions, from several millions to multi billions deals. When he came back from New York, Noel worked at Alantra, an investment bank, as a Director and completed two successful IPOs. With his background, Noel demonstrates a strong capability in complex financial structuring and investment processes. Following this, Müller served as CFO at ConReal Swiss AG and other startup companies.

Joleen completed her Bachelor of Science in Biology at Tel-Aviv University, Israel June 2017. In February 2018 she joined the Gaucher Unit and the pediatric Hematology-Oncology Unit, as a clinical study coordinator. The Gaucher Unit at Shaare Zedek Medical Center is the world's largest with more than 900 patients over 30 years. In 2019 she joined the International Working Group on Gaucher Disease (IWGGD) as the board secretary assistant, and in 2021, she gained her MBA degree in Pharma and Health System at the Ono-Academic College, Israel. Her research work on Gaucher disease (GD) focuses on chaperone therapy for both GD (neuronopathic and non-neuronopathic) and GBA1-related Parkinson's disease, digital health, patient-reported outcomes measures, neuronopathic GD focusing on type IIIC, and different patient's registries.

Jonathan Arnon. LLB. MBA (both from the Hebrew University of Jerusalem) Admitted to the Israeli Bar Association in 2005. A commercial and civil lawyer and also practice as a qualified mediator. Previously, acted as an entrepreneur and held different roles in several Israeli technological start-up companies.

Doreen is an internationally experienced manager with more than 15 years of experience in managing all administrative and executive day-to-day operations of start-up companies, including human resources management, strategic communications and marketing, as well as support in all areas of the management board and supervisory board. In her current role, Doreen oversees the executive processes and operational development of necessary strategic operations. Prior to joining Agyany Pharmaceuticals, Doreen worked for several years in various positions at Centogene AG and Arcensus GmbH, most recently as Chief of Staff. Before that, she was Head of Strategic Management at the Albrecht-Kossel-Institute at the University of Rostock. Doreen holds a degree in business administration.

Mia Horowitz graduated from the department of Genetics, The Weizmann Institute of Science, Rehovot Israel, in 1980. Following a two and half years as a post-doctoral fellow under the supervision of Prof. P. A. Sharp at MIT, Massachusetts, USA, she joined the Weizmann institute as an investigator. She initiated a project aiming at understanding the molecular biology underlying Gaucher disease in 1985. In 1990 she moved to Tel Aviv University and in 1998 became a full professor. She served as department head between 1999-2003.

A neurologist and Movement Disorders (MD) specialist, the director of one of the largest MD centers in the Middle East, placed at the Chaim Sheba Medical Center (SMC), located in Ramat Gan, 10 kilometers from Tel-Aviv, in Israel. She finished her medical studies at the Faculty of Medicine, Tel Aviv University (TAU), and residency in the Department of Neurology, at SMC (1991-1997). Following a MD fellowship, she founded the Parkinson’s disease (PD) and Movement Disorders Clinic in 1999, which became the Movement Disorders Institute in 2014, a center of knowledge and excellence in clinical care and research, implementing advanced and unique treatment methodologies for movement disorders. Her research has been focused on PD as well as neurogenetic movement disorders. Since 2016 she is an associate professor of Neurology at the Faculty of Medicine, TAU, and since 2019 she is the chair of the department of Neurology and Neurosurgery at TAU.

Per Svenningsson is a physician-researcher. His research interests include idiopathic Parkinson´s disease, GBA-Parkinson’s disease, atypical parkinsonism and rare movement disorders with regards to both motor and non-motor aspects. The studies are at molecular and cellular levels both in preclinical models and in specimens from patients. The goal is to identify novel targets for improved diagnostics and disease-modifying therapy. Optimization of predictive and diagnostic biomarkers are sought for in the laboratory. At the clinics, he is conducting clinical trials with therapies to slow down progression of idiopathic Parkinson´s disease, GBA-Parkinson’s disease or atypical parkinsonism or to treat debilitating symptoms of the disease.